Department of Medicine, Division of Gastroenterology/Hepatology, Northwestern University, 676 N St Clair Street, Suite 1400, Chicago, IL 60611, USA.
Department of Medicine, Division of Gastroenterology/Hepatology, Northwestern University, 676 N St Clair Street, Suite 1400, Chicago, IL 60611, USA.
Gastroenterol Clin North Am. 2022 Mar;51(1):107-121. doi: 10.1016/j.gtc.2021.10.007. Epub 2022 Jan 8.
Opioid-related constipation encompasses constipation directly caused by opioid use (opioid-induced constipation [OIC]) as well as pre-existing constipation worsened by opioid use (opioid-exacerbated constipation [OEC]). Over-the-counter laxatives should be used as first-line agents for both OIC and OEC, given their efficacy, low cost, and high safety profiles. Symptoms of OIC and responses to therapy can be assessed with the Bowel Function Index. Individuals with OIC refractory to laxatives may be responsive to peripherally acting μ-opioid receptor antagonists. Although data supporting the superiority of one prescription agent over another is lacking, all have proven effective for the treatment of OIC.
阿片类药物相关性便秘包括直接由阿片类药物使用引起的便秘(阿片类药物诱导性便秘[OIC])以及因阿片类药物使用而恶化的预先存在的便秘(阿片类药物加重性便秘[OEC])。鉴于其疗效、低成本和高安全性,非处方泻药应作为 OIC 和 OEC 的一线药物。OIC 和治疗反应的症状可以用肠道功能指数来评估。对泻药无反应的 OIC 患者可能对周围作用的μ-阿片受体拮抗剂有反应。尽管缺乏支持一种处方药物优于另一种药物的数据,但所有药物都已被证明对 OIC 的治疗有效。